Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (RNA-Seq)

ABSTRACT: Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (RNA-Seq)

PROVIDER: PRJNA789269 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR17261935.fastq.gz	Fastqsanger.gz
	SRR17261936.fastq.gz	Fastqsanger.gz
	SRR17261937.fastq.gz	Fastqsanger.gz
	SRR17261938.fastq.gz	Fastqsanger.gz
	SRR17261939.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 8

Similar Datasets

Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes

Project description:Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes

| PRJNA789265 | ENA

Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (ChIP-Seq)

Project description:Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (ChIP-Seq)

| PRJNA789270 | ENA

Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (RNA-Seq)

Project description:To analyse the effect of Cinobufagin to human acute myeloid leukemia cell lines, HL60 and Kasumi-1.

2022-12-09 | GSE190996 | GEO

Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes (ChIP-Seq)

Project description:To analyse the effect of Cinobufagin to human acute myeloid leukemia cell lines, HL60 and Kasumi-1.

2022-12-09 | GSE190995 | GEO

MYC interacts with the G9a histone methyltransferase to drive transcriptional repression and tumorigenesis

Project description:MYC is an oncogenic driver that regulates transcriptional activation and repression, yet molecular mechanisms of MYC transformation remain unclear. We demonstrate that MYC interacts with the G9a H3K9-methyltransferase complex to control transcriptional repression. Inhibiting G9a hinders MYC chromatin binding at MYC-repressed genes and de-represses gene expression to antagonize cellular transformation. By identifying the MYC Box II region as essential for MYC-G9a interaction, a long-standing missing link between MYC transformation and gene repression is unveiled. In breast cancer, anti-proliferative sensitivity to G9a pharmacological inhibition associates with MYC sensitivity and the basal subtype. Inhibiting G9a in vivo suppresses MYC-dependent basal breast tumor growth. Our findings reveal G9a as an epigenetic regulator of MYC-mediated transcriptional repression and a therapeutic vulnerability in MYC-driven cancers.

2018-10-08 | GSE115024 | GEO

MYC interacts with the G9a histone methyltransferase to control transcriptional repression in cancer

Project description:MYC is a master regulator of transcriptional activation and repression that mediates diverse physiological and disease functions, including hematopoiesis, aging, and oncogenesis, yet its essential co-regulators remain unclear. We demonstrate that MYC interacts with and regulates the G9a H3K9 methyltransferase complex to control transcriptional repression in cancer. Inhibiting G9a hinders MYC binding, shifts repressive epigenetic locales to an active state, and de-represses gene expression to antagonize MYC-dependent cellular processes. MYC requires MYC Box II region for its interaction with G9a, providing a mechanism for this region essential for transcriptional repression. In treatment models of MYC-dependent basal breast cancer, genetically inhibiting G9a decreases tumour growth. Anti-proliferative sensitivity to G9a small molecule inhibitors correlates with sensitivity to MYC knockdown and associates with the basal subtype. Our findings illustrate an epigenetic model of MYC-mediated transcriptional repression in driving oncogenesis and establishes G9a as a therapeutic vulnerability in MYC-driven cancers.

2018-10-08 | GSE100335 | GEO

Anti-proliferative effect of Cinobufagin on acute myeloid leukemia cells with repression of c-Myc pathway associated genes

Project description:This SuperSeries is composed of the SubSeries listed below.

2022-12-09 | GSE190997 | GEO

IRF8-dependent control of pDC terminal differentiation and MYC repression

Project description:A switch from MYC expression in bone marrow progenitors to MYCL expression in terminal dendrtitic cell (DC) subsets occurs during DC development. The present study identifies the precise stage during DC development when this switch occurs, and identifies a role for IRF8 in control of this switch. IRF8 is found to be required for both MYC repression and MYCL induction during DC specification in vivo.

2021-06-10 | GSE176508 | GEO

Activation and repression by oncogenic Myc shapes tumour-specific gene expression profiles

Project description:In mammalian cells, the Myc oncoprotein binds to thousands of promoters. During mitogenic stimulation of primary lymphocytes, Myc promotes an increase in expression of virtually all genes. In contrast, Myc-driven tumour cells differ from normal cells in expression of specific sets of up- and downregulated genes that have significant prognostic value. To understand this discrepancy, we studied the consequences of inducible expression and depletion of Myc in human cells and murine tumour models. Changes in Myc levels activate and repress specific sets of direct target genes that are characteristic of Myc-transformed tumour cells. Three factors account for this specificity: First, the magnitude of response parallels the change in occupancy by Myc at each promoter. Functionally distinct classes of target genes differ in the E-box sequence bound by Myc, arguing that different cellular responses to physiological and oncogenic Myc levels are controlled by promoter affinity. Secondly, Myc both positively and negatively affects transcription initiation independent of its effect on transcriptional elongation. Third, complex formation with Miz1 mediates repression of multiple target genes by Myc and the ratio of Myc and Miz1 bound to each promoter correlates with the direction of response. Myc, Miz1 and RNA polymerase II ChIPseq as well as RNAseq experiments in two human cancer cell lines and murine carcinoma cells as well as fibroblasts from Miz1M-bM-^HM-^FPOZ mice. All sequencing experiment were performed on an Illumina Genome Analyzer IIx.

2014-07-10 | E-GEOD-44672 | biostudies-arrayexpress

IRF8-dependent control of pDC terminal differentiation and MYC repression

Project description:IRF8-dependent control of pDC terminal differentiation and MYC repression

| PRJNA736457 | ENA